CONSOLIDATED STATEMENT OF CASH FLOWS (USD $)	3 Months Ended		83 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (504,876)	$ (656,002)	$ (15,902,174)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	40,156	40,156	1,177,515
Technology impairment	0	0	690,000
Common stock issued for services	0	0	318,500
Stock options and warrants	86,278	16,019	3,804,511
(Increase) decrease in assets
Prepaid drug product for testing	(197,692)	99,000	(249,056)
Other current assets	(93,347)	(11,349)	(157,464)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	125,059	(38,828)	419,957
Net cash used in operating activities	(544,422)	(551,004)	(9,898,211)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	0	(884,710)
Net cash used in investing activities	0	0	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	13,812,373	305,665	27,182,704
Net cash from financing activities	13,812,373	305,665	27,602,704
NET INCREASE (DECREASE) IN CASH	13,267,951	(245,339)	16,819,783
Cash, beginning of period	3,551,832	534,046	0
Cash, end of period	16,819,783	288,707	16,819,783
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	0	0	1,362,613
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 0	$ 210,755